Watson Pharmaceuticals (now Actavis) received final approval from the U.S. FDA for Abbreviated New Drug Application (ANDA) 075961 on January 25, 2002. This clearance positions the company to introduce the generic drug, immediately enhancing its market footprint and offering a lower-cost alternative to name-brand treatments.